Skip to main content

PetIQ Stock Forecast, Price & News

-0.57 (-1.43 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume393,579 shs
Average Volume342,462 shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PETQ News and Ratings via Email

Sign-up to receive the latest news and ratings for PetIQ and its competitors with MarketBeat's FREE daily newsletter.

PetIQ logo

About PetIQ

PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.


See More Headlines

Industry, Sector and Symbol

Industry Drugs, proprietaries, & sundries
Current SymbolNASDAQ:PETQ
Year FoundedN/A

Sales & Book Value

Annual Sales$709.43 million
Cash Flow$1.52 per share
Book Value$11.60 per share


Net Income$-11,450,000.00




Market Cap$1.14 billion
Next Earnings Date8/5/2021 (Estimated)


Overall MarketRank

1.58 out of 5 stars

Medical Sector

445th out of 2,044 stocks

Drugs, Proprietaries, & Sundries Industry

6th out of 14 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

PetIQ (NASDAQ:PETQ) Frequently Asked Questions

Is PetIQ a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PetIQ in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PetIQ stock.
View analyst ratings for PetIQ
or view top-rated stocks.

What stocks does MarketBeat like better than PetIQ?

Wall Street analysts have given PetIQ a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PetIQ wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is PetIQ's next earnings date?

PetIQ is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for PetIQ

How were PetIQ's earnings last quarter?

PetIQ, Inc. (NASDAQ:PETQ) issued its quarterly earnings results on Wednesday, May, 5th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.35. PetIQ had a positive trailing twelve-month return on equity of 4.47% and a negative net margin of 10.13%.
View PetIQ's earnings history

How has PetIQ's stock price been impacted by COVID-19 (Coronavirus)?

PetIQ's stock was trading at $22.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PETQ shares have increased by 74.5% and is now trading at $39.41.
View which stocks have been most impacted by COVID-19

What guidance has PetIQ issued on next quarter's earnings?

PetIQ issued an update on its FY 2021 earnings guidance on Wednesday, May, 12th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $950 million-$950 million, compared to the consensus revenue estimate of $938.13 million.

What price target have analysts set for PETQ?

4 equities research analysts have issued 1-year target prices for PetIQ's shares. Their forecasts range from $45.00 to $175.00. On average, they expect PetIQ's stock price to reach $78.75 in the next year. This suggests a possible upside of 99.8% from the stock's current price.
View analysts' price targets for PetIQ
or view top-rated stocks among Wall Street analysts.

Who are PetIQ's key executives?

PetIQ's management team includes the following people:
  • Mr. McCord Christensen, Chairman & CEO (Age 49)
  • Mr. John Newland, Chief Financial Officer (Age 57)
  • Mr. Michael A. Smith, Exec. VP of Products Division (Age 44, Pay $970.96k)
  • Ms. Susan Sholtis, Pres (Age 54)
  • Mr. Robert Michael Herrman, Gen. Counsel & Sec. (Age 52)
  • Dr. Lauren Olavessen D.V.M., Sr. VP & Chief Medical Officer

What is Cord Christensen's approval rating as PetIQ's CEO?

10 employees have rated PetIQ CEO Cord Christensen on Cord Christensen has an approval rating of 89% among PetIQ's employees.

Who are some of PetIQ's key competitors?

What other stocks do shareholders of PetIQ own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PetIQ investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Exelixis (EXEL), Intel (INTC), CVS Health (CVS), QUALCOMM (QCOM), Editas Medicine (EDIT) and Gilead Sciences (GILD).

When did PetIQ IPO?

(PETQ) raised $86 million in an IPO on Friday, July 21st 2017. The company issued 5,700,000 shares at $14.00-$16.00 per share. Jefferies and William Blair acted as the underwriters for the IPO and Oppenheimer, Raymond James and SunTrust Robinson Humphrey were co-managers.

What is PetIQ's stock symbol?

PetIQ trades on the NASDAQ under the ticker symbol "PETQ."

Who are PetIQ's major shareholders?

PetIQ's stock is owned by many different institutional and retail investors. Top institutional investors include Waddell & Reed Financial Inc. (9.40%), BlackRock Inc. (7.47%), Geneva Capital Management LLC (4.61%), Riverbridge Partners LLC (3.90%), Ensign Peak Advisors Inc (3.67%) and Russell Investments Group Ltd. (2.85%). Company insiders that own PetIQ stock include John Newland, Mark L First, Michael A Smith, Robert Michael Herrman, Ronald Kennedy, Susan Sholtis and Will Santana.
View institutional ownership trends for PetIQ

Which major investors are selling PetIQ stock?

PETQ stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Russell Investments Group Ltd., Riverbridge Partners LLC, Geneva Capital Management LLC, Northern Trust Corp, Gabelli Funds LLC, UBS Group AG, and Boston Partners. Company insiders that have sold PetIQ company stock in the last year include John Newland, Mark L First, Michael A Smith, Robert Michael Herrman, Ronald Kennedy, Susan Sholtis, and Will Santana.
View insider buying and selling activity for PetIQ
or view top insider-selling stocks.

Which major investors are buying PetIQ stock?

PETQ stock was acquired by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., Envestnet Asset Management Inc., RE Advisers Corp, Dimensional Fund Advisors LP, Rothschild & Co. Asset Management US Inc., Geode Capital Management LLC, Peregrine Capital Management LLC, and BlackRock Inc.. Company insiders that have bought PetIQ stock in the last two years include John Newland, and Robert Michael Herrman.
View insider buying and selling activity for PetIQ
or or view top insider-buying stocks.

How do I buy shares of PetIQ?

Shares of PETQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PetIQ's stock price today?

One share of PETQ stock can currently be purchased for approximately $39.41.

How much money does PetIQ make?

PetIQ has a market capitalization of $1.14 billion and generates $709.43 million in revenue each year. The company earns $-11,450,000.00 in net income (profit) each year or $1.07 on an earnings per share basis.

How many employees does PetIQ have?

PetIQ employs 1,015 workers across the globe.

What is PetIQ's official website?

The official website for PetIQ is

Where are PetIQ's headquarters?

PetIQ is headquartered at 923 S. Bridgeway Pl., EAGLE ID, 83616.

How can I contact PetIQ?

PetIQ's mailing address is 923 S. Bridgeway Pl., EAGLE ID, 83616. The company can be reached via phone at 208-939-8900 or via email at [email protected]

This page was last updated on 5/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.